MedTrace Logo

The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19

NCT04891250 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-02-03

No results posted yet for this study

Summary

The study aims to test whether Ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length of stay in ICU and transition probabilities to ICU (ventilator).

Conditions

Interventions

DRUG

Ivermectin

Treatment of SARS Cov-2 patients with Ivermectin

OTHER

Prophylaxis

Treatment of high risk population with Ivermectin as prophylaxis

Sponsors & Collaborators

  • Ministry of Health, Zambia

    collaborator OTHER_GOV

  • University of Zambia

    collaborator OTHER

  • Centre for Infectious Disease Research in Zambia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • Zambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04891250 on ClinicalTrials.gov